C4X Discovery sells Orexin-1 drug candidate to Indivior for £15.95 million
LONDON, UK: C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announced the execution of an asset purchase agreement for Indivior PLC...
Mark Crossley appointed CEO of Indivior PLC
RICHMOND: Indivior PLC announced that effective today, the Board of Directors has appointed Mark Crossley as Chief Executive Officer. Shaun Thaxter, in mutual agreement with...